| ￥3500 | |
| Z04033-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 17.43 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS，(pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized CD7, His, Cynomolgus, His Tag at 1 μg/ml (100 μL/well) on the plate. Dose response curve for Human SECTM1, hFc Tag with the EC50 of 0.17 μg/ml determined by ELISA. »
The purity of CD7, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
CD7, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD7, also known as Leu-9, is an approximately 40 kDa glycosylated and palmitoylated transmembrane protein in the immunoglobulin superfamily.CD7 is expressed on T cells, NK cells , myeloid progenitor cells, and CD19 B progenitor cells. Among CD8 T cells, the CD7-bright population preferentially contains naïve and memory cells, while more weak expressors are primarily effector cells. |
| Synonyms | CD7 molecule; CD7; LEU-9; Tp40; TP41; GP40 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
